

FUZEON® PROCEDURE and REQUIRED INFORMATION FORM

Fax non-urgent requests to PerformRx Pharmacy Services at **866-369-6038** or urgent requests to **866-533-5491**. Urgent requests should be reserved for those situations in which applying the standard procedure may seriously jeopardize the enrollee's life, health, or ability to regain maximum function.

To speak to a representative, call 866-533-5490. **Form must be completed for processing.**



Patient Name: _____ Patient ID # _____ Patient Phone # _____

Patient Address: _____

Physician Name: _____ NPI # _____

Physician Address: _____

Physician Phone # _____ Fax # _____ Contact Person _____

Fuzeon Rx: _____ Physician Signature: _____

Is the member/patient currently residing in a Long-Term Care (LTC) facility? (please check) Yes No

PART A: Directions for Fuzeon® Coverage Determination Request:

- For Coverage Determination, fax all requested information in **PART B** or **PART C** (whichever is applicable) to PerformRx Pharmacy Services. Complete *Fuzeon® Medication History Form* for Coverage determination of initial and *HIV-RNA Tracking Form* for continuation of Fuzeon®.

PART B: Required Medical Information for Initial Coverage determination of Fuzeon®

1. A detailed medication history complete the "Fuzeon® Medication History Form" documenting prior treatment failures, including corresponding HIV-1 RNA levels and CD4 counts.
2. Has the patient tried and failed one oral drug regimen that was based on genotype and phenotype sensitivity testing? (circle) Yes / No If no, please provide a medical reason for not utilizing one sensitivity assisted oral drug regimen prior to ordering Fuzeon. Attach additional information if necessary.

3. Current HIV-1 RNA level and CD4 count - include dates of lab work (either comment below or fax lab reports). Use *HIV-1 RNA Tracking Form* and fax with request.

4. Has the patient tried at least 2 different drug regimens containing 2 different NRTIs and PIs? (Circle) Yes / No If yes please indicate below. If no, please provide a documented medical reason for not utilizing 2 different regimens containing 2 different NRTIs and PIs - Attach additional information if necessary.

5. Please comment on the patient level of adherence to previous oral medications.

6. Please indicate background drug therapy intended to be given with Fuzeon:

7. Documentation of baseline (or when the member was on oral medication) genotypic and phenotypic sensitivity analysis. Fax lab reports with request.

PART C: For Reauthorization After 16 Weeks of Therapy (Each reauthorization will be for an additional 16 weeks – same criteria applies each time)

1. Reauthorization requires updated HIV-RNA and CD4 levels, as well as specific documented clinical benefits (e.g. weight gain, etc) the patient is experiencing by using Fuzeon®. Use *HIV-1 RNA Tracking Form* and fax with request.
2. Please indicate current background drug therapy:
